Cell line · CVCL_0105
Papers293
1 to 20 of 293
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The VCPIP1-UBE3A Deubiquitination-Ubiquitination Cascade Contributes to Castration-Resistant Prostate Cancer Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Primary tumor-derived lactate primes prostate cancer cells for a dormant fate. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Graphene Oxide-Doped CuMOF Nanoplatform Enhances Chemodynamic Therapy and Suppresses CYP2J2-Mediated Linoleic Acid Metabolism in Castration-Resistant Prostate Cancer. | Int J Nanomedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer. | Cancer Chemother Pharmacol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Combined Topoisomerase Inhibition and FLASH Radiotherapy in Head and Neck Carcinoma Biomodels. | MedComm (2020) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Castration-resistant prostate cancer cells are addicted to the high activity of cyclin-dependent kinase 2. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MYDGF as a telomerase activator and therapeutic target for osteoarthritis. | Adv Biotechnol (Singap) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. | Br J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactate-induced H3K4me3 histone mark promotes PLOD1-driven prostate cancer invasion. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs. | Mol Biomed | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Interaction between CD82 and integrin αVβ3 selectively regulates collective movement of tumor cells via endolysosomal trafficking. | Cell Mol Life Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
A Bioinspired Three-Dimensional High-Curvature Nano-Interface Integrated Microfluidic Chip for Small Extracellular Vesicles Enrichment and Machine Learning-Assisted Prostate Cancer Precision Diagnosis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ROS-Responsive Nanobubbles for Dual-Enhanced Ultrasound and Magnetic Resonance Imaging of Tumor Oxidative Stress. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0105/papers